Related Experiment Videos

Atorvastatin: beyond lipid-lowering effects in the diabetic population

Julie Ramos1, Qamar A Khan, Martin Thoenes

  • 1Emory University School of Medicine, Division of Cardiology, 69 Jesse Hill Drive SE, No. C247, Atlanta, GA 30303, USA.

Future Cardiology
|October 7, 2009
PubMed

Insights

Statins like atorvastatin significantly reduce cardiovascular events and mortality. This cholesterol-lowering drug also offers additional benefits, particularly for diabetic patients, in preventing strokes.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Statins are primary treatments for coronary artery disease and high cholesterol.
  • Atorvastatin, a daily 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitor, is proven to reduce cardiovascular mortality.
  • Emerging research highlights atorvastatin's pleiotropic effects beyond lipid reduction.

Purpose of the Study:

  • To summarize the established and emerging benefits of atorvastatin.
  • To emphasize atorvastatin's role in cardiovascular risk management, especially in diabetic populations.

Main Methods:

  • Review of clinical trials and scientific literature on atorvastatin.
  • Analysis of data regarding lipid-lowering effects and pleiotropic actions.

Main Results:

  • Atorvastatin effectively lowers cholesterol and reduces cardiovascular mortality events.
  • Pleiotropic effects include benefits in stroke prevention and cardiovascular risk reduction in diabetics.

Conclusions:

  • Atorvastatin is a crucial therapeutic agent for managing cardiovascular health.
  • Its benefits extend to improved outcomes in diabetic patients, including stroke prevention.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...